I et andet længerevarende, 26- ugers kontrolleret forsøg var forekomsten af EPS 14, 8% for aripiprazol - behandlede patienter og 15, 1% for olanzapin- behandlede patienter.
In another long-term 26-week controlled trial, the incidence of EPS was 14.8% for aripiprazole-treated patients and 15.1% for olanzapine-treated patients.